GRAIL's Galleri Test Shows Significant Increase in Early Cancer Detection at ASCO 2026
GRAIL, Inc. presented the results of its PATHFINDER 2 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the Galleri multi-cancer early detection (MCED) test. The study involved 35,878 participants aged 50 and older, demonstrating that the Galleri test significantly increased cancer detection rates when used alongside standard screenings for breast, colorectal, cervical, and lung cancers. The test detected 71% of new cancers in stages I-III, with a 6.5-fold increase in detection rates. The Galleri test also showed a high specificity of 99.6%, indicating a low false-positive rate. The study highlights the potential of the Galleri test to transform early cancer detection and improve treatment outcomes.